文献速递真菌感染

侵袭性霉菌病治疗的新药理学机会

New pharmacological opportunities for the treatment of invasive mould diseases.
PubMed 文献 · J Antimicrob Chemother · 2017-01-01

本文综述了近期随机研究对侵袭性霉菌感染预防和治疗决策的影响。伏立康唑是确诊或疑似侵袭性曲霉病的首选药物,艾沙康唑在侵袭性霉菌病中疗效与伏立康唑相似且药物相关不良事件更少,联合治疗在特定亚组中改善生存。

要点

  • 伏立康唑是确诊或疑似侵袭性曲霉病的首选药物。
  • 艾沙康唑每日一次给药,在侵袭性霉菌病中疗效与伏立康唑相似且不良事件更少。
  • 伏立康唑联合阿尼芬净在GM阳性亚组中改善生存。

核心结论

  • 艾沙康唑在侵袭性霉菌病中疗效与伏立康唑相似且药物相关不良事件更少。
  • 伏立康唑联合阿尼芬净在血清和/或BALF GM阳性确诊亚组中改善生存。

研究设计与样本

  • 本文为综述,汇总近期随机研究结果。

主要发现

  • 伏立康唑治疗确诊或疑似侵袭性曲霉病的应答率显著高于两性霉素B脱氧胆酸盐,且严重药物相关不良事件更少。
  • 艾沙康唑治疗侵袭性霉菌病的死亡率与伏立康唑相似,药物相关不良事件更少。
  • 艾沙康唑对毛霉病感染有效,但患者数量少,尚待确认。
  • 伏立康唑联合阿尼芬净与伏立康唑单药治疗侵袭性曲霉病的总应答率相似,但联合治疗改善了血清和/或BALF GM阳性确诊亚组的生存。

临床怎么用

  • 伏立康唑可作为确诊或疑似侵袭性曲霉病的首选治疗。
  • 艾沙康唑可考虑用于侵袭性霉菌病,尤其需减少药物相互作用或不良事件时。
  • 对GM阳性的侵袭性曲霉病患者可考虑伏立康唑联合阿尼芬净治疗。

局限性

  • 艾沙康唑治疗毛霉病的患者数量少,结论尚待确认。
  • 联合抗霉菌治疗的临床数据库有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Recently, several randomized studies have been published that will shape treatment decisions in the prevention and management of invasive mould infections. Liposomal amphotericin B is an option for empirical or targeted treatment of invasive aspergillosis or mucormycosis, but for prophylaxis therapy, the triazole class now predominates. The triazole voriconazole is currently regarded as a drug of choice for the treatment of proven or probable invasive aspergillosis, and has shown significantly higher response rates than amphotericin B deoxycholate in this setting, with fewer severe drug-related adverse events. Isavuconazole, the newest triazole agent, offers the advantages of once-daily dosing, a wider spectrum of antifungal activity than voriconazole, predictable pharmacokinetics and fewer CYP enzyme-mediated drug interactions. A recent large randomized clinical trial showed mortality to be similar under isavuconazole or voriconazole in patients with invasive mould disease, with fewer drug-related adverse events in isavuconazole-treated patients. Another study has indicated that isavuconazole is also effective in mucormycosis infections but patient numbers were small and confirmation is awaited. Experimental studies combining different drug classes with antimould activity have been promising, but the clinical database is limited. A large randomized trial of combination therapy compared voriconazole plus the echinocandin anidulafungin versus voriconazole monotherapy in patients with invasive aspergillosis. Results showed the overall response rate to be similar, but combination therapy improved survival for the subpopulation of patients in whom the diagnosis was confirmed by serum and/or bronchoalveolar lavage fluid galactomannan positivity. This active field of research is likely to continue evolving rapidly in the coming years.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Ledoux MP, Toussaint E, Denis J, et al. New pharmacological opportunities for the treatment of invasive mould diseases. J Antimicrob Chemother. 2017. PMID: 28355467. doi:10.1093/jac/dkx033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。